KindredBio and X-Body Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health

SAN FRANCISCO, CA and WALTHAM, MA, USA. (March 31, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and KindredBio will develop and commercialize these antibodies. KindredBio will provide an upfront payment, […]

Kindred Bio Announces Initiation of Pivotal Clinical Study for SentiKin™ in Dogs

SentiKin™, KindredBio’s third lead product candidate, is being developed for the treatment of post-operative pain in dogs. SAN FRANCISCO, California. (March 28, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for […]

KindredBio Appoints Dr. Blake Hawley as Chief Commercial Officer, Announces Upcoming Inclusion in Russell 2000

Blake Hawley, D.V.M., Worldwide Director of Global Digital and Former General Manager of U.K. & Ireland, Russia, Central Eastern Europe, and Australasia at Hill’s Pet Nutrition, to Join KindredBio SAN FRANCISCO, California. (March 24, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. […]

KindredBio Announces Proposed Public Offering

SAN FRANCISCO, California. (March 18, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number […]

Kindred Biosciences Announces Fourth Quarter and Year End 2013 Financial Results

San Francisco, CA. (March 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. KindredBio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results.